Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
INOVIO (NASDAQ: INO) announced the approval of equity grants to Dr. Michael John Sumner, the newly appointed Chief Medical Officer, as part of its 2022 Inducement Plan. The grants included a restricted stock unit (RSU) award of 105,000 shares, vesting over three years, and a stock option to purchase 160,000 shares at an exercise price of $1.73. Both awards are contingent on Dr. Sumner's continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects INOVIO's commitment to attract top talent in biotechnology.
INOVIO (NASDAQ: INO) has appointed Dr. Michael Sumner as its new Chief Medical Officer. With over 25 years of experience in clinical development and regulatory affairs, Dr. Sumner will oversee INOVIO's clinical-stage pipeline, including clinical operations and regulatory affairs. He previously served as CMO of Orexo AB and held roles at Novartis Pharmaceuticals and other major pharmaceutical companies. His expertise in guiding companies through product approvals is expected to bolster INOVIO's efforts in developing DNA medicines aimed at infectious diseases and cancers.
INOVIO (NASDAQ: INO) announced promising results from a Phase 1/2 trial evaluating INO-5401 and INO-9012 in combination with Libtayo® for newly diagnosed glioblastoma (GBM). The study reported a median overall survival (OS) of 32.5 months for MGMT methylated patients, outperforming historical data. The combination therapy showed a tolerable safety profile and elicited immune responses, with activated T cells identified. Dr. David Reardon will present these findings at ASCO on June 6, 2022, emphasizing the potential of this novel treatment approach for GBM patients.
INOVIO (NASDAQ: INO) announced that President and CEO Jacqueline Shea, along with Jeffrey Skolnik, SVP of Clinical Development for Oncology and HPV Therapeutics, will participate in a fireside chat and individual investor meetings at the Jefferies 2022 Healthcare Conference on June 8, 2022, at 1:00 PM EDT. A webcast of the presentation will be available on the INOVIO Investor Relations Events page. The company focuses on developing DNA medicines for infectious diseases, cancer, and HPV-associated diseases.
INOVIO (NASDAQ: INO) has shifted its focus to a heterologous booster strategy for its COVID-19 vaccine candidate INO-4800, discontinuing the Phase 3 INNOVATE trial. The decision is based on positive T cell immune response data showing a 6.3-fold increase with INO-4800 as a booster. Additionally, the company is revising plans for VGX-3100 after FDA feedback, requiring more trials for HPV treatment. INOVIO reported Q1 2022 revenue of $199,000, down from $371,000, and a net loss of $79.1 million, or $0.36 per share. Jacqueline Shea has been appointed as the new CEO.
INOVIO has appointed Jacqueline Shea, Ph.D., as President and CEO, effective immediately. Dr. Shea, who joined INOVIO in March 2019 as COO, will succeed Dr. J. Joseph Kim, who has resigned from the board. Dr. Shea possesses over 25 years of leadership experience in biotech, including roles at Aeras and Emergent BioSolutions. The board looks forward to her leadership during challenging times and plans to appoint her as a director post the annual stockholders' meeting on May 16, 2022. Dr. Shea aims to advance INOVIO's DNA medicines technology, improving global patient health.
INOVIO (NASDAQ: INO) will release its first quarter 2022 financial results after market close on May 10, 2022. A live conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The company continues to focus on DNA medicines for infectious diseases, cancer, and HPV-related conditions, with candidates VGX-3100 and INO-4800 undergoing evaluation in Phase 3 trials. For more information, visit www.inovio.com.
Geneos Therapeutics announced a successful $17 million Series A2 financing led by Flerie Invest, enhancing its clinical trial for advanced hepatocellular carcinoma (HCC). The funding will expand the GT-30 Phase Ib/IIa trial from 24 to 36 patients, utilizing the personalized cancer vaccine GNOS-PV02 combined with a DNA-encoded cytokine and PD-1 checkpoint inhibitor. Dr. Ted Fjällman joins the Board, bringing European investor expertise. The company reported tumor reduction in over half of the initial patients treated and aims to release further efficacy data in 2022.
INOVIO (NASDAQ: INO) announced that CEO Dr. Joseph Kim will participate in a fireside chat and 1x1 meetings at Oppenheimer's 32nd Annual Healthcare Conference on March 15, 2021, at 8:00 AM ET. The event will focus on the company's work in developing DNA medicines for infectious diseases and cancer treatments, including Phase 3 trials for VGX-3100 and INO-4800, a COVID-19 vaccine. A webcast of the presentation can be accessed via the INOVIO Investor Relations page.
INOVIO (NASDAQ: INO) reported financial results for Q4 and year-end 2021, with total revenue of $839,000 and $1.8 million respectively, down from $5.6 million and $7.4 million in 2020. The net loss widened to $106.9 million, or $0.50 per share, compared to a net loss of $24.3 million the previous year. Key developments include ongoing clinical trials for COVID-19 vaccine INO-4800, with plans to amend its Phase 3 trial endpoint to focus on severe disease. Other advancements include completed enrollments for various therapeutic programs, highlighting INOVIO's commitment to combating infectious diseases and cancer.